Inflammatory Bowel Disease


Evaluate the probability of disease progression in a Crohn’s disease patient by providing a personal serogenetic profile.
PROMETHEUS® Crohn’s Prognostic combines serologic and genetic markers in an innovative blood test that quantifies a patient’s individual probability of developing disease complications over time. Serologic markers include ASCA IgA, ASCA IgG and proprietary markers anti-CBir1, anti-I2, anti-OMPC, and DNAse sensitive pANCA. Genetic markers include NOD2 variants (SNPS 8, 12, 13). The objective information from Crohn’s Prognostic may allow physicians to stratify patients, assist in optimizing management strategies and assist with risk/benefit healthcare provider/patient discussions.
Sample insurance correspondence for PROMETHEUS® Crohn’s Prognostic
References
Plevy, Silverberg, Lockton et al. Combined archaeology, genetic, and inflammatory markers differentiate non-IBD, Crohn’s Disease, and ulcerative colitis patients. Inflammatory Bowel Diseases. 2013; 19(6):1139-48.
Lichtenstein, Targan, Dubinsky et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn’s Disease behavior. Inflammatory Bowel Diseases. 2011; 17(12):2488-96.
Crohn’s Prognostic is a laboratory-developed test that was developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and is performed exclusively in our high complexity CLIA certified (05D0917432) and College of American Pathologists (CAP) accredited (6805501) clinical laboratory. As a laboratory developed test, it has not been cleared or approved by the US FDA. The test may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. Prometheus is a registered trademark of Prometheus Laboratories Inc, San Diego, California. All other trademarks or service marks are the property of their respective owners. This material is provided for general information purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician.